H.R. 5575 · 118th Congress (2023–2025)
Safe Medicine Act
This bill addresses issues related to the manufacture of drugs, including essential medicines.
The Department of Health and Human Services, the Department of Defense, and the Department of Veterans Affairs must jointly develop and implement a strategy to increase the domestic production of essential medicines, medical countermeasures, and critical inputs.
If the Food and Drug Administration determines that a drug or active pharmaceutical ingredient is manufactured in a country that may be producing contaminated drugs or ingredients due to systemic manufacturing-related problems, the labeling for that drug or ingredient must have a boxed warning about the potential for contamination.
For government procurement purposes, the President's authority to waive certain purchasing requirements that discriminate against foreign products may not be used to waive any preferences for goods that are essential medicines, medical countermeasures, or critical inputs.
Show official title
To direct the Secretaries of Health and Human Services, Defense, and Veterans Affairs to end American over-dependence on Chinese pharmaceuticals by encouraging the growth of a robust domestic medicine supply chain for generic drugs, to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Trade
This bill’s path
This is H.R. 5575’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Bill Posey (R-FL-8)
- Policy area
- Health
- Subjects
- Cardiovascular and respiratory health
- Chemical and biological weapons
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Emergency medical services and trauma care
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Manufacturing
9 more
- Medical tests and diagnostic methods
- Military medicine
- Military procurement, research, weapons development
- Nuclear weapons
- Public contracts and procurement
- Strategic materials and reserves
- Trade agreements and negotiations
- Veterans' medical care
- Worker safety and health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 5 committee actions · Sep 19, 2023 – Dec 17, 2024
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Veterans' Affairs, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Referred to Trade
Referred to the Subcommittee on Trade.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Trade → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Safe Medicine Act
Display title, Short title · Introduced in House
To direct the Secretaries of Health and Human Services, Defense, and Veterans Affairs to end American over-dependence on Chinese pharmaceuticals by encouraging the growth of a robust domestic medicine supply chain for generic drugs, to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination, and for other purposes.
Official title · Introduced in House